Literature DB >> 3324089

Nocardia infection in splenectomized patients: case reports and a review of the literature.

E A Abdi1, J C Ding, I A Cooper.   

Abstract

Opportunistic infections are increasingly becoming a problem in cancer patients amongst whom infection with Nocardia species is particularly difficult to detect due to the capricious natural history of the disease. Three cases of Nocardia infection in patients who had undergone splenectomy for haematological malignancy are presented. These cases illustrate the diverse mode of presentation, the natural history and the difficulties in early and accurate diagnosis of Nocardia infection. Despite the difficulties in arriving at the correct diagnosis, these cases highlight the importance of early institution of appropriate antibiotic therapy. Antibiotics should be given in adequate doses to control the initial infection and be maintained for a prolonged period to prevent relapses.

Entities:  

Mesh:

Year:  1987        PMID: 3324089      PMCID: PMC2428323          DOI: 10.1136/pgmj.63.740.455

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  20 in total

1.  Prevalence of Nocardia asteroides in sputa examined by a tuberculosis diagnostic laboratory.

Authors:  T S HOSTY; C McDURMONT; L AJELLO; L K GEORG; G L BRUMFIELD; A A CALIX
Journal:  J Lab Clin Med       Date:  1961-07

2.  THE IMPORTANCE OF THE SPLEEN IN RESISTANCE TO INFECTION.

Authors:  D H Morris; F D Bullock
Journal:  Ann Surg       Date:  1919-11       Impact factor: 12.969

3.  Diagnostic and therapeutic considerations in Nocardia asteroides infection.

Authors:  D L Palmer; R L Harvey; J K Wheeler
Journal:  Medicine (Baltimore)       Date:  1974-09       Impact factor: 1.889

4.  Nocardia asteroides infection complicating neoplastic disease.

Authors:  L S Young; D Armstrong; A Blevins; P Lieberman
Journal:  Am J Med       Date:  1971-03       Impact factor: 4.965

5.  Bacterial infections in pediatric Hodgkin's disease: relationship to radiotherapy, chemotherapy and splenectomy.

Authors:  S S Donaldson; E Glatstein; K L Vosti
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

Review 6.  Pulmonary infection in the compromised host: part I.

Authors:  D M Williams; J A Krick; J S Remington
Journal:  Am Rev Respir Dis       Date:  1976-08

Review 7.  Complications of splenectomy. Etiology, prevention, and management.

Authors:  E C Ellison; P J Fabri
Journal:  Surg Clin North Am       Date:  1983-12       Impact factor: 2.741

Review 8.  Postsplenectomy infection.

Authors:  E L Francke; H C Neu
Journal:  Surg Clin North Am       Date:  1981-02       Impact factor: 2.741

9.  Nocardial infections in the United States, 1972-1974.

Authors:  B L Beaman; J Burnside; B Edwards; W Causey
Journal:  J Infect Dis       Date:  1976-09       Impact factor: 5.226

10.  Results of therapy in systemic nocardiosis.

Authors:  P J Geiseler; B R Andersen
Journal:  Am J Med Sci       Date:  1979 Nov-Dec       Impact factor: 2.378

View more
  5 in total

1.  Silent nocardia cerebral abscesses in treated dermatomyositis.

Authors:  M W Savage; C E Clarke; G M Yuill
Journal:  Postgrad Med J       Date:  1990-07       Impact factor: 2.401

Review 2.  Nocardia species: host-parasite relationships.

Authors:  B L Beaman; L Beaman
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

Review 3.  The medically important aerobic actinomycetes: epidemiology and microbiology.

Authors:  M M McNeil; J M Brown
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

4.  Differential Role of Rapamycin and Torin/KU63794 in Inflammatory Response of 264.7 RAW Macrophages Stimulated by CA-MRSA.

Authors:  Rebekah K H Shappley; Thomas Spentzas
Journal:  Int J Inflam       Date:  2014-04-01

5.  A Case of Bilateral Nocardia francinia Adrenal Abscesses in an Intravenous Drug-Using Splenectomized Patient With Tricuspid Endocarditis.

Authors:  Lesley E Jackson; Mahmoud Shorman
Journal:  Open Forum Infect Dis       Date:  2018-06-15       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.